Baird Financial Group
KPTI icon

Baird Financial Group’s Karyopharm Therapeutics KPTI Stock Holding History

Baird Financial Group’s Portfolio KPTI Stock Details KPTI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$166K Buy
29,791
+1,798
+6% +$13.7K ﹤0.01% 1793
2025
Q4 		$206K Buy
27,993
+2,061
+8% +$12.6K ﹤0.01% 1730
2025
Q3 		$170K Buy
25,932
+15,400
+146% +$82.9K ﹤0.01% 1747
2025
Q2 		$45.4K Buy
+10,532
New +$51.7K ﹤0.01% 1758
2025
Q1 		– Sell
-2,987
Closed -$30.3K – 1802
2024
Q4 		$30.3K Buy
2,987
+467
+19% +$5.65K ﹤0.01% 1742
2024
Q3 		$31.4K Buy
2,520
+67
+3% +$833 ﹤0.01% 1735
2024
Q2 		$31.9K Buy
2,453
+1,066
+77% +$17.6K ﹤0.01% 1741
2024
Q1 		$31.4K Buy
1,387
+467
+51% +$8.19K ﹤0.01% 1739
2023
Q4 		$11.9K Hold
920
– – ﹤0.01% 1702
2023
Q3 		$18.5K Hold
920
– – ﹤0.01% 1698
2023
Q2 		$24.7K Sell
920
-878
-49% -$37.8K ﹤0.01% 1676
2023
Q1 		$105K Buy
1,798
+525
+41% +$25.9K ﹤0.01% 1655
2022
Q4 		$65K Buy
1,273
+60
+5% +$4.16K ﹤0.01% 1665
2022
Q3 		$99K Buy
1,213
+85
+8% +$6.35K ﹤0.01% 1669
2022
Q2 		$76K Sell
1,128
-8
-0.7% -$734 ﹤0.01% 1752
2022
Q1 		$126K Sell
1,136
-185
-14% -$23.1K ﹤0.01% 1775
2021
Q4 		$127K Buy
1,321
+142
+12% +$14.2K ﹤0.01% 1848
2021
Q3 		$103K Buy
1,179
+48
+4% +$4.98K ﹤0.01% 1841
2021
Q2 		$175K Buy
1,131
+90
+9% +$13.1K ﹤0.01% 1706
2021
Q1 		$164K Buy
1,041
+14
+1% +$2.95K ﹤0.01% 1655
2020
Q4 		$239K Buy
1,027
+91
+10% +$21.1K ﹤0.01% 1452
2020
Q3 		$205K Buy
936
+44
+5% +$10.8K ﹤0.01% 1404
2020
Q2 		$253K Buy
892
+29
+3% +$8.58K ﹤0.01% 1356
2020
Q1 		$249K Sell
863
-4
-0.5% -$1.1K ﹤0.01% 1260
2019
Q4 		$249K Buy
+867
New +$188K ﹤0.01% 1393

Other funds holding KPTI

CC
Commodore Capital New York $1.73B AUM 298.96% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
APM
Avidity Partners Management Dallas, Texas $936M AUM 195% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
CCM
Catalio Capital Management New York $479M AUM 140.7% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
IC
Ikarian Capital Dallas, Texas $1.23B AUM 600.17% 1-Year Est. Return
AAA
Affinity Asset Advisors New York $1.94B AUM 374.45% 1-Year Est. Return

Baird Financial Group's KPTI Position: Q1 2026 in Review

Baird Financial Group increased its Karyopharm Therapeutics (KPTI) stake by 6.4% in Q1 2026, buying an estimated $13.7K and bringing the position to 29,791 shares worth $166K. The position accounts for ﹤0.01% of the portfolio, ranked #1793.

Baird Financial Group first reported a position in KPTI in Q4 2019 and has held it in 25 quarters since. The position peaked at $253K in Q2 2020. 77 funds tracked by Wall St. Rank hold KPTI as of Q1 2026.

  • Baird Financial Group held 29,791 shares of Karyopharm Therapeutics worth $166K as of Q1 2026.
  • Baird Financial Group bought 1,798 Karyopharm Therapeutics shares in Q1 2026, an estimated $13.7K.
  • Karyopharm Therapeutics made up ﹤0.01% of Baird Financial Group's portfolio in Q1 2026, its #1793 holding.
  • Baird Financial Group first reported a position in Karyopharm Therapeutics in Q4 2019 and has held it in 25 quarters since.
  • Baird Financial Group's Karyopharm Therapeutics position peaked at $253K in Q2 2020.
  • 77 funds tracked by Wall St. Rank held Karyopharm Therapeutics as of Q1 2026.

Based on Baird Financial Group's 13F filing for Q1 2026, filed 14 May 2026.